MONASTROL Struktur

MONASTROL

Bezeichnung:MONASTROL

CAS-Nr329689-23-8

Englisch Name:MONASTROL

CBNumberCB92130960

SummenformelC14H16N2O3S

Molgewicht292.35

MOL-Datei329689-23-8.mol

MONASTROL physikalisch-chemischer Eigenschaften

Schmelzpunkt	190-193℃ (ethanol )
Siedepunkt	441.3±55.0 °C(Predicted)
Dichte	1.34±0.1 g/cm3 (20 ºC 760 Torr)
RTECS-Nr.	UV6262400
storage temp.	under inert gas (nitrogen or Argon) at 2-8°C
Löslichkeit	DMSO (Slightly), Ethyl Acetate (Slightly), Methanol (Slightly, Heated)
Aggregatzustand	White to light yellow solid.
pka	9.63±0.10(Predicted)
Farbe	White to Off-White
Sensitive	Light Sensitive

Gefahreninformationscode (GHS)

MONASTROL Chemische Eigenschaften,Einsatz,Produktion Methoden

Verwenden
Monastrol is a small molecule that inhibits mitotic kinesin Eg5 and arrests cells in mitosis with monopolar spindles (1, 2).Monastrol is an anticancer agent against MCF-7 tumor cells (3).
Definition
ChEBI: A member of the class of thioureas that is 3,4-dihydropyrimidine-2(1)-thione substituted by a 3-hydroxyphenyl group at position 4, a methyl group at position 6 and a ethoxycarbonyl group at position 5.
Biologische Aktivität
monastrol is a cell-permeable small molecule inhibitor of the mitotic kinesin, eg5. like other kinesins, eg5 can drive the movement of microtubules in vitro.
in vitro
previous study found that monastrol did not inhibit progression through s and g2 phases of the cell cycle or centrosome duplication. the mitotic arrest due to monastrol was also reversible rapidly. chromosomes in monastrol-treated cells frequently had both sister kinetochores attached to microtubules extending to the center of the monoaster. monastrol also inhibited bipolar spindle formation in xenopus egg extracts, however, monastrol did not prevent the targeting of eg5 to the monoastral spindles that form [1].
in vivo
previous study investigated the rat pk and tk of lasom 65, a monastrol derivative. results showed that lasom 65 had good bioavailability and linear pk after oral doses. lasom 65 distributed consistently in lung and fatty tissues. other investigated tissues presented smaller penetration ratios. adverse symptoms were observed only after iv administration, and regressed 3 h after dosing. no statistical differences were found for serum analysis, body weight and relative organ weight, indicating no acute toxicological effects. [2].
IC 50
14 μm
Einzelnachweise
[1] kapoor tm,mayer tu,coughlin ml,mitchison tj. probing spindle assembly mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin, eg5. j cell biol.2000 sep 4;150(5):975-88.
[2] torres bg,ucha fde t,pigatto mc,azeredo fj,haas se,dallegrave e,canto rf,eifler-lima vl,dalla costa t. pre-clinical pharmacokinetics and acute toxicological evaluation of a monastrol derivative anticancer candidate lasom 65 in rats. xenobiotica.2014 mar;44(3):254-63.

MONASTROL Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Send Inquriy